Navigating the Rise of Cannabidiol: Trends, Challenges, and Future Directions
DOI:
Abstract
The use of cannabidiol (CBD) as an alternative treatment for chronic pain and anxiety is experiencing a rapid rise in Sweden. This study explores current trends, patient and healthcare provider perceptions, regulatory challenges, and barriers to broader CBD adoption. Employing a mixed-methods design, quantitative surveys and qualitative interviews are conducted with CBD users and healthcare professionals across various regions in Sweden. Findings indicate that CBD usage is highest in urban areas, driven by greater accessibility and wellness culture. Patients report moderate to high satisfaction, particularly for chronic pain management, although self-medication practices and lack of professional guidance are common. Healthcare providers exhibit cautious optimism, citing the need for further clinical validation and regulatory clarity. Safety concerns such as inaccurate product labeling and financial barriers, including the absence of insurance coverage for CBD, emerge as significant obstacles. Demographic analysis reveals differing usage patterns based on age but minimal gender differences. The study highlights the urgent need for standardized dosing guidelines, rigorous randomized controlled trials (RCTs), and stronger regulatory frameworks to ensure quality and equity in CBD treatment. Sweden’s progressive healthcare landscape positions it to play a leading role in global efforts to integrate CBD responsibly into mainstream medicine. Future research must bridge clinical, regulatory, and economic gaps to support CBD’s evolution as a legitimate therapeutic option worldwide.
Downloads
Views : 233
Downloads : 96
References
M. Wright, P. Di Ciano, and B. Brands, “Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence,” Cannabis and Cannabinoid Research, vol. 5, no. 3, pp. 191–196, Sep. 2020.
Swedish Medical Products Agency, “Swedish Medical Products Agency,” Läkemedelsverket, [Online]. Available: https: //www.lakemedelsverket.se/en. [Accessed: Jan. 12, 2025].
B. Ross, T. Trojian, and D. M. Cushman, “Physician Perceptions of Cannabidiol (CBD) and Cannabis in Sports Medicine and Performance,” Translational Sports Medicine, vol. 2023, 2023.
J. L. Wiley, C. K. Gourdet, and B. F. Thomas, Cannabidiol: Science, Marketing, and Legal Perspectives [Online]. Research Triangle Park, NC: RTI Press, Apr. 2020.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), “Cannabidiol (CBD) products in Europe: Regulatory frameworks and market developments,” 2024. [Online]. Available: https: //www.emcdda.europa.eu.
J. L. Q. Simei, J. D. R. Souza, J. F. Pedrazzi, F. S. Guimarães, A. C. Campos, A. Zuardi, J. E. C. Hallak, and J. A. S. Crippa, “Research and clinical practice involving the use of cannabis products, with emphasis on cannabidiol: A narrative review,” Pharmaceuticals, vol. 17, no. 12, 2024.
G. Cásedas, M. Yarza-Sancho, and V. López, “Cannabidiol (CBD): A systematic review of clinical and preclinical evidence in the treatment of pain,” Pharmaceuticals (Basel), vol. 17, no. 11, 2024
B. Fischer et al., “Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update,” Int. J. Drug Policy, vol. 99, Jan. 2022.
N.-F. Parrella, A. T. Hill, P. G. Enticott, P. Barhoun, I. S. Bower, and T. C. Ford, “A systematic review of cannabidiol trials in neurodevelopmental disorders,” Pharmacol. Biochem. Behav., vol. 230, Sep. 2023.
S. D. Lichenstein, “THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis' primary cannabinoids,” Curr. Addict. Rep., vol. 9, no. 4, pp. 473–485, Dec. 2022.
A. H. Russo, “Cannabinoids in the management of difficult to treat pain,” Therapeutics and Clinical Risk Management, vol. 4, no. 1, pp. 245–259, 2008.
T. Hurzeler, J. Watt, W. Logge, E. Towers, A. Suraev, N. Lintzeris, P. Haber, and K. C. Morley, “Neuroimaging studies of cannabidiol and potential neurobiological mechanisms relevant for alcohol use disorders: a systematic review,” J. Cannabis Res., vol. 6, no. 1, Mar. 2024.
F. Shahbazi, V. Grandi, A. Banerjee, and J. F. Trant, “Cannabinoids and cannabinoid receptors: The story so far,” iScience, vol. 23, no. 7, 2020.
E. Johnson, M. Kilgore, and S. Babalonis, “Cannabidiol (CBD) product contamination: Quantitative analysis of Δ9-tetrahydrocannabinol (Δ9-THC) concentrations found in commercially available CBD products,” Drug Alcohol Depend., vol. 237, Aug. 2022.
C. F. Coelho et al., “The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials,” Life (Basel), vol. 14, no. 11, 2024.
M. S. García-Gutiérrez, F. Navarrete, A. Gasparyan, A. Austrich-Olivares, F. Sala, and J. Manzanares, “Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders,” Biomolecules, vol. 10, no. 11, 2020.
K. Novale, “The potential of cannabidiol (CBD) as a treatment for anxiety disorders,” J. Pharm. Toxicol., vol. 6, no. 2, pp. 25–28, 2023.
Z. Breijyeh, B. Jubeh, S. A. Bufo, R. Karaman, and L. Scrano, “Cannabis: A toxin-producing plant with potential therapeutic uses,” Toxins (Basel), vol. 13, no. 2, 2021.
K. F. Boehnke, J. J. Gagnier, L. Matallana, and D. A. Williams, “Cannabidiol use for fibromyalgia: Prevalence of use and perceptions of effectiveness in a large online survey,” J. Pain, vol. 22, no. 5, pp. 556–566, May 2021.
S. Nielsen, L. Picco, B. Murnion, B. Winters, J. Matheson, M. Graham, G. Campbell, L. Parvaresh, K. E. Khor, B. Betz-Stablein, M. Farrell, N. Lintzeris, and B. Le Foll, “Opioid-sparing effect of cannabinoids for analgesia: An updated systematic review and meta-analysis of preclinical and clinical studies,” Neuropsychopharmacology, vol. 47, no. 7, pp. 1315–1330, Jun. 2022.
Z. Hu, Z. Qin, J. Xie, Y. Qu, and L. Yin, “Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects,” Biomedicine & Pharmacotherapy, vol. 176, Jul. 2024.
J. D. R. Souza, J. C. Pacheco, G. N. Rossi, B. O. de-Paulo, A. W. Zuardi, F. S. Guimarães, J. E. C. Hallak, J. A. Crippa, and R. G. Dos Santos, “Adverse effects of oral cannabidiol: An updated systematic review of randomized controlled trials (2020–2022),” Pharmaceutics, vol. 14, no. 12, 2022.
L. Palagini, M. Miniati, V. Caruso, G. Alfi, P. A. Geoffroy, K. Domschke, D. Riemann, A. Gemignani, and S. Pini, “Insomnia, anxiety and related disorders: a systematic review on clinical and therapeutic perspective with potential mechanisms underlying their complex link,” Neuroscience Applied, vol. 3, 2024.
H. Meissner and M. Cascella, “Cannabidiol (CBD) in clinical care,” StatPearls [Internet], updated May 7, 2024. Treasure Island (FL): StatPearls Publishing, 2025. Available: https: //www.statpearls.com.
L. H. R. Whitaker, C. Page, C. Morgan, A. W. Horne, and P. T. K. Saunders, “Endometriosis: cannabidiol therapy for symptom relief,” Trends in Pharmacological Sciences, vol. 45, no. 12, pp. 1150-1161, Dec. 2024.
United Nations, Report of the International Narcotics Control Board for 2023, E/INCB/2023/1, 2024. [Online]. Available: https: //www.incb.org/documents/Publications/AnnualReports /AR2023/Annual_Report/E_INCB_2023_1_eng.pdf. [Accessed: Jan. 13, 2025].
J. W. Creswell and J. D. Creswell, Research Design (5th ed.). Thousand Oaks, CA: SAGE Publications, 2018.
S. Tenny and M. A. Varacallo, “Evidence-Based Medicine,” StatPearls [Internet], updated Sep 10, 2024. Treasure Island (FL): StatPearls Publishing, 2025. Available: https: //www.statpearls.com.
N. Kopec, “CBD and THC in Sweden,” HempKing Blog, Sep. 30, 2023. [Online]. Available: https: //hempking.eu/en/cbd-and-thc-in-sweden/. [Accessed: Jan. 13, 2025].
A. A. Binkowska, N. Jakubowska, A. Redeł, S. Laskowska, S. Szlufik, and A. Brzezicka, “Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study,” Front. Psychiatry, vol. 15, 2024.
